Navigation Links
Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
Date:5/22/2013

NEW YORK, May 22, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) today is hosting the first international conference devoted to advancing new treatments for lupus nephritis, a serious kidney complication of lupus affecting up to 60 percent of patients. The conference launched a new international alliance of researchers specializing in lupus nephritis – the Lupus Nephritis Trials Network (LNTN).

More than 50 of the world's top experts on lupus and the kidney came together to focus on two critical questions: 1) Which new medicines have the greatest potential to treat lupus nephritis; 2) How should these medications be tested in clinical trials?

LRI Partners with LNTN for New Lupus Treatments
The conference is a part of an ongoing partnership between the LNTN and the LRI.  LNTN unites over 100 academic investigators from around the world to conduct clinical trials in lupus nephritis and to simplify the process of testing new drugs by developing standardized clinical trial methods. The Network has already secured U.S. government and European Union funding for three trials of new approaches to the treatment of lupus nephritis.

"We are grateful to the Lupus Research Institute for being a founding supporter of LNTN and for sponsoring this meeting, a first in the field of lupus nephritis," noted Betty Diamond , MD, Center for Autoimmune and Musculoskeletal Diseases at The Feinstein Institute for Medical Research. "Concentrating on highly innovative approaches, the Network is addressing a pressing need for safer and more effective treatments."  

"The LRI and LNTN are natural allies in the fight against kidney damage caused by lupus," commented Margaret Dowd , President and CEO of the Lupus Research Institute. "This conference demonstrates how breakthrough discoveries the LRI funded in lupus nephritis are informing the de
'/>"/>

SOURCE Lupus Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... June 3, 2007 - Schering-Plough Corp. announced ... maintenance chemotherapy with,Caelyx (pegylated liposomal doxorubicin hydrochloride),significantly ... with,metastatic breast cancer with infrequent and manageable ... presented,today at the 43rd Annual Meeting of ...
... of Largest Ever Phase III Clinical Trial ... /PRNewswire-FirstCall/ --,GlaxoSmithKline today announced final results of ... investigational MAGE-A3,Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3,positive ... Cell Lung Cancer,(NSCLC). These data were presented ...
Cached Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... that is helping people perform better in and out of ... performance, and memory has caught the attention of Shane Michaels, ... the day-to-day grind, fatigue is the reason most people simply ... want, whether that means staying focused at work, getting the ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... 30, 2014 Regenerative Medicine Solutions (RMS) ... clinics in Nashville, Tennessee. RMS welcomes the launch of ... the expansion of a new treatment center for the ... Sleep Apnea Institute to Nashville, the hope is to ... apnea: both diagnosed and undiagnosed. With Nashville being a ...
(Date:9/30/2014)... Two revolutionary procedures now being utilized by Dr. ... a far less painful and far more effective remedy ... felt electric shock waves surge through your teeth as you ... possible you already know the impact of receding gums,” says ... in West Palm Beach, and a Fellow in the Academy ...
Breaking Medicine News(10 mins):Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... , New Report Examines How Reform May Impact ... 17 According to a new report from State Coverage Initiatives, ... issue of how new or modified federal rules will impact health ... the states. , , The report, ...
... vampires, cancer tumors require an ample supply of blood to ... up like raisins and die. To that end, Dr. ... Pharmacology, Sackler School of Medicine, and her team of researchers ... to the tumor. Ferrying a variety of existing life-saving therapies ...
... CA An important analysis conducted by Children,s Hospital ... optimal dietary intakes of vitamin K to prevent age-related ... cardiovascular disease, and possibly cancer (1). Vitamin K is ... Swiss chard, and is either not present or present ...
... , DEL MAR, Calif., Sept. 17 In ... nerve pain said that their pain was one of the top ... that people with diabetic nerve pain recognize the condition,s impact on ... discussed the condition with a healthcare provider, just slightly less than ...
... also found younger adults at higher risk , THURSDAY, Sept. ... more than 8 million adults in the United States seriously ... to contemplate taking their own lives. , In addition to ... a plan to do so, and 1.1 million actually attempted ...
... , , LOUISVILLE, Ky., Sept. ... and AAF products, is proud to announce the MEGAcel(TM) I ... Helior media used in the MEGAcel I ... drop than conventional micro-fiberglass media. With a significantly lower operating resistance, energy consumption ...
Cached Medicine News:Health News:Health Care Reform and American Federalism 2Health News:Killing cancer like a vampire slayer 2Health News:New vitamin K analysis supports the triage theory 2Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 2Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 3Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 4Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 5Health News:8.3 Million U.S. Adults Considered Suicide Last Year 2Health News:AAF(R) Announces MEGAcel(TM) I Filter with Helior(TM) Media 2
6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 4.5 mm tying platform. Serrated handle with polished finish....
Medicine Products: